Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
← catalyst calendarNCT07218783 · readout in 955 d
Sponsored by SpyGlass Pharma, Inc. (industry) · SGP — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
400estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-15 | actual | When the study began enrolling |
| Primary completion | 2029-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cataract
- Glaucoma
- Ocular Hypertension
Interventions
- Drug: Bimatoprost Implant System
- Device: SpyGlass IOL
- Drug: Timolol Maleate Ophthalmic Solution, 0.5%
- Device: Commercial IOL
Primary outcomes
what the primary-completion date above is the date OFMean IOP Reduction from Baseline (mmHg)
measured Weeks 2 and 6, and Month 3
BCDVA 20/40 or better
measured Month 6
Permalink · SGP's whole pipeline · Catalyst calendar · Every registered study · What changed